Louisiana State Employees Retirement System’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.49M | Sell |
27,800
-100
| -0.4% | -$12.6K | 0.06% | 243 |
|
|
2025
Q1 | $3.09M | Sell |
27,900
-200
| -0.7% | -$22.1K | 0.06% | 258 |
|
|
2024
Q4 | $3.84M | Buy |
28,100
+100
| +0.4% | +$13.7K | 0.07% | 212 |
|
|
2024
Q3 | $3.23M | Sell |
28,000
-500
| -2% | -$57.6K | 0.06% | 269 |
|
|
2024
Q2 | $3.92M | Sell |
28,500
-100
| -0.3% | -$13.8K | 0.08% | 193 |
|
|
2024
Q1 | $3.94M | Buy |
28,600
+1,000
| +4% | +$138K | 0.08% | 202 |
|
|
2023
Q4 | $3.64M | Sell |
27,600
-100
| -0.4% | -$13.2K | 0.08% | 203 |
|
|
2023
Q3 | $3.12M | Sell |
27,700
-800
| -3% | -$90K | 0.07% | 212 |
|
|
2023
Q2 | $2.69M | Buy |
28,500
+2,900
| +11% | +$273K | 0.06% | 263 |
|
|
2023
Q1 | $2.59M | Sell |
25,600
-100
| -0.4% | -$10.1K | 0.07% | 239 |
|
|
2022
Q4 | $3.07M | Buy |
25,700
+300
| +1% | +$35.8K | 0.08% | 197 |
|
|
2022
Q3 | $2.7M | Buy |
25,400
+300
| +1% | +$31.9K | 0.08% | 200 |
|
|
2022
Q2 | $2.42M | Buy |
25,100
+300
| +1% | +$28.9K | 0.06% | 241 |
|
|
2022
Q1 | $2.43M | Buy |
24,800
+400
| +2% | +$39.2K | 0.06% | 293 |
|
|
2021
Q4 | $2.08M | Buy |
24,400
+300
| +1% | +$25.5K | 0.05% | 394 |
|
|
2021
Q3 | $2.31M | Sell |
24,100
-400
| -2% | -$38.4K | 0.06% | 293 |
|
|
2021
Q2 | $2.38M | Buy |
24,500
+200
| +0.8% | +$19.5K | 0.06% | 294 |
|
|
2021
Q1 | $2.36M | Buy |
+24,300
| New | +$2.36M | 0.06% | 282 |
|